Acadia Pharmaceuticals

Acadia Pharmaceuticals

Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.

History

Acadia Pharmaceuticals was founded in 1993. The company initially focused on drug discovery and development for neurological and related central nervous system disorders. Over the years, Acadia has developed a pipeline of product candidates, with a particular focus on treatments for Parkinson's disease psychosis and other neuropsychiatric conditions.

Products

Acadia Pharmaceuticals is best known for its drug Pimavanserin, marketed under the brand name Nuplazid. Nuplazid is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors.

Research and Development

Acadia Pharmaceuticals has a robust research and development program aimed at discovering and developing new treatments for central nervous system disorders. The company's pipeline includes investigational drugs for conditions such as schizophrenia, major depressive disorder, and dementia-related psychosis.

Collaborations and Partnerships

Acadia Pharmaceuticals has engaged in various collaborations and partnerships to advance its research and development efforts. These collaborations have included partnerships with academic institutions, research organizations, and other pharmaceutical companies.

Financial Performance

Acadia Pharmaceuticals is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol ACAD. The company has experienced significant growth in recent years, driven by the commercial success of Nuplazid and its ongoing research and development activities.

Related pages

• Biopharmaceutical
• Central nervous system
• Parkinson's disease
• Psychosis
• Serotonin